Literature DB >> 28507490

Cognitive impairment in patients with severe psoriasis.

Luiza Marek-Józefowicz1, Marcin Jaracz2, Waldemar Placek3, Rafał Czajkowski1, Alina Borkowska2.   

Abstract

INTRODUCTION: Psoriasis is a chronic inflammatory skin disease, in which an important role is played by psychological factors. AIM: To evaluate the frontal cognitive functions in patients with psoriasis.
MATERIAL AND METHODS: The study included 188 subjects (97 patients with psoriasis and 91 healthy controls). To assess the dorsolateral prefrontal cortex functions, the Trail Making Test and the Stroop test were applied. Severity of psoriasis was assessed by means of the PASI index.
RESULTS: Compared to healthy subjects, psoriatics scored lower in neuropsychological tests assessing memory and executive functions.
CONCLUSIONS: Cognitive dysfunction disclosed by neuropsychological assessment of frontal functions was evident in patients with psoriasis.

Entities:  

Keywords:  cognitive functions; depression; executive functions; prefrontal cortex; psoriasis

Year:  2017        PMID: 28507490      PMCID: PMC5420603          DOI: 10.5114/ada.2017.67074

Source DB:  PubMed          Journal:  Postepy Dermatol Alergol        ISSN: 1642-395X            Impact factor:   1.837


Introduction

Psoriasis is a chronic disease significantly impairing psychosocial functioning of patients, and is considered to be a severe psychosomatic disease. The results of current research indicate that psychological factors play an important role in the etiology of many somatic diseases. The need to take psychological factors into account for dermatological disorders has been increasingly emphasized [1-6]. Cognitive functions enable one to adapt to shifting environmental conditions. They are important in perception, judgment, and decision-making, as well as building self-esteem. They include information processing, attention, learning, language abilities, memory and complex mental processes, such as executive functions. In coping with the disease, particularly relevant are decision-making processes related to the activity of several brain structures, especially those determining information processing, evaluation and understanding of the different situations, and emotional control. Based on the data from neuroimaging studies, it has been concluded that the main structures of the brain, important for decision-making, are ventromedial and dorsolateral prefrontal cortex. The ventromedial prefrontal cortex is responsible for the emotional aspect of decision-making, and many studies show that a final decision is associated with the activity of this structure. The dorsolateral prefrontal cortex is responsible for the analysis of problematic situations, understanding and validation of information pouring in from our surroundings and their quick integration [7]. In these processes, a key role is played by executive functions, which are based on working memory. They are essential for the proper conduct and integration of complex cognitive processes such as planning, conceptual thinking, problem solving, understanding of the situation, and adaptation to changing environmental conditions. Functioning of the working memory is mainly dependent on the activity within the dorsolateral prefrontal cortex. Due to its connection with the limbic system and the subcortical structures (as well as other areas of the cerebral cortex), this area is responsible for the most complex cognitive and emotional functions. Working memory is a short-term memory, which allows for the correct integration of information, depending on the requirements of a given situation, which is possible due to the “online processes”. It is also responsible for timed storage of information about current activities and the ability to switch to a new way of acting [8]. Evaluation of the efficiency of working memory is being carried out with specific neuropsychological tests, designed for the assessment of its various aspects. In the research on psoriasis, attention tends to be drawn to the greater prevalence of depressive symptoms, which may impact the efficacy of cognitive functions [9-11]. Many studies indicate that symptoms of depression are associated with a decrease in psychomotor speed, impaired attention as well as with disturbances of memory and executive functions, related to hypofrontality in course of the depressive state [12-14].

Aim

The aim of this study was to evaluate prefrontal cognitive dysfunctions in patients with severe psoriasis (PASI > 10 points) in the context of demographic and clinical factors, as well as depressive symptoms.

Material and methods

Subjects

Ninety-seven patients with psoriasis (62 men and 35 women) hospitalized in the Department of Dermatology in Bydgoszcz, Poland, were enrolled in the current study. The patients’ age ranged from 18 to 60 years (mean: 44.1 ±13.0 years). The control group consisted of 91 healthy individuals (39 men and 52 women), aged 22–65 years (mean: 41.0 ±10.7). Exclusion criteria were: age over 65 and under 18 years, history of head injuries, comorbid severe neurological and autoimmune diseases, drug or alcohol addiction, intake of immunosuppressive drugs in the past 3 months, and treatment with oral agents for psoriasis in the past three months. Examination and assessment of severity of dermatological lesions (Psoriasis Area and Severity Index – PASI) was conducted by one physician, which was also the case during the administration of TMT and Stroop tests. The diagnosis of psoriasis was based on the clinical picture and data from an interview. When necessary, a biopsy was performed for histopathological evaluation. The study was approved by the Nicolaus Copernicus University Torun, Collegium Medicum Bydgoszcz Research Bioethics Committee. All subjects gave their written consent to participate in the study after the nature of procedures was fully explained to them.

Methods

Psoriasis Area and Severity Index (PASI)

This scale, developed by Fredrikson and Pettersson in 1978, is one of the most commonly used tools for the evaluation of psoriasis severity. The value is the sum of the products of PASI for the four parts of the body. PASI maximum value is 72, the minimum 0. Higher scores indicate greater severity of the clinical lesions [15, 16].

Trail Making Test (TMT)

The test consists of two parts, A and B. In part A the subject is asked to connect, as quickly as possible, a series of circles numbered 1 to 25, in a numerical order. In part B, the task of the subject is to connect alternately numbered circles marked with letters as quickly as possible, according to the formula: 1-A 2-B-3-C, etc. Part A examines psychomotor speed, and the efficiency of visual spatial coordination, part B is a measure of visual-spatial working memory and set shifting [17]. The time of performance in both parts of the test was analyzed in the current study.

Stroop Color-Word Interference Test

This test is designed to evaluate verbal working memory and attention efficiency. It consists of two parts: RCNb (Reading Color Name In Black) and NCWd (Naming Color of Word-Different). The first part of the test requires the subject to read, as quickly as possible, words denoting colors which were printed black on white. In the NCWd part, the subject is asked to call as quickly as possible the color of the words’ print. Print color does not coincide, however, with the color, which name is written. Here, after learning an initial criterion for action, the subject needs to switch to another, while the previous criterion is still remembered [18]. The time of performance in both parts of the test was analyzed in the current study.

Beck Depression Inventory (BDI)

The scale consists of 21 items relating to various symptoms of depression. Within each category, there are four possible answers indicating the intensity of the symptoms, starting with its absence (0) up to very high severity (3). The rating assigned to each response ranges from 0 to 3 points. Minimum overall score is 0 points, and maximum is 63 points. Threshold for the recognition of depression was adopted as 12 points [19, 20].

Statistical analysis

The distribution of variables was assessed by means of the Shapiro Wilk test. As the distribution of variables tested did not meet the normality criterion, nonparametric tests were applied for the statistical analysis. The significance of differences between groups was assessed by means of the Mann Whitney U-tests and Spearman’s rho coefficient was applied for the assessment of correlations between variables.

Results

The PASI score in patients enrolled fell in the range of 10.1–58.7 points, with mean 21.9 ±9.4 SD points. The results of the neuropsychological tests in patients with psoriasis were significantly worse than those of the healthy controls. Afflicted subjects presented significantly lower psychomotor speed (TMT test A), diminished efficiency of spatial working memory and set shifting ability (TMT B), as well as poorer verbal working memory and attention, as evidenced by the longer time of performance in Stroop Test A and B (Table 1).
Table 1

The results of TMT-A and B, Stroop A and B tests in patients with psoriasis and healthy controls group

TestPatients with psoriasis Mean value; 25–75%Healthy controls Mean value, 25–75%
TMT A36.0; 29.0–44.021.0; 17.0–28.5**
TMT B65.0; 55.0–78.040.0; 33.0–53.0**
Stroop A36.0; 31.0–45.021.0; 17.0–28.0**
Stroop B60.0; 55.0–69.047.0; 38.0–55.0**
Beck Depression Inventory13.0; 9.0–18.02.0; 0.0–5.0**

Significant differences between the groups

p < 0.001, U-test of Mann-Whitney.

The results of TMT-A and B, Stroop A and B tests in patients with psoriasis and healthy controls group Significant differences between the groups p < 0.001, U-test of Mann-Whitney. There was a significant correlation between the results of neuropsychological tests, and the age of the respondents in both investigated groups. Lower results obtained in neuropsychological tests were associated with higher age both in psoriasis patients and healthy control groups. A higher level of education correlated with better performance in neuropsychological tests, except for no association between the level of education and the Stroop B test results in the psoriasis patients group (Table 2).
Table 2

Correlations between the results of neuropsychological tests and the severity of depressive symptoms on Beck Depression Inventory, and the age and level of education, in the group of patients and healthy subjects (Spearman’s rho)

TestAgeLevel of education
Patients with psoriasisHealthy controlsPatients with psoriasisHealthy controls
TMT A0.38*–0.03–0.28*–0.29*
TMT B0.27*0.40*–0.16–0.29*
Stroop A0.43*–0.04–0.30*–0.43*
Stroop B0.32*0.11–0.17–0.41*
Beck Depression Inventory–0.020.16–0.02–0.15

Significant correlation at p < 0.05.

Correlations between the results of neuropsychological tests and the severity of depressive symptoms on Beck Depression Inventory, and the age and level of education, in the group of patients and healthy subjects (Spearman’s rho) Significant correlation at p < 0.05. In the patient group there was no association between the severity of psoriasis changes indicated by the PASI score, duration of the last exacerbation of the disease and the results of neuropsychological tests. Longer duration of the disease correlated with worse neuropsychological performance, except for the results of Stroop B Test (Table 3).
Table 3

Correlations between neuropsychological test results and severity of psoriasis in PASI score and duration of the disease and last exacerbation in the group of patients with psoriasis (Spearman’s rho)

TestPASIDuration of illnessDuration of last exacerbation
TMT A0.080.22*–0.16
TMT B0.050.22*–0.13
Stroop A0.180.35*–0.17
Stroop B0.080.16–0.16

Significant correlation at p < 0.05.

Correlations between neuropsychological test results and severity of psoriasis in PASI score and duration of the disease and last exacerbation in the group of patients with psoriasis (Spearman’s rho) Significant correlation at p < 0.05.

Discussion

The main finding of the present study is that patients with psoriasis present impairment of working memory, when compared to healthy controls. They perform significantly worse in neuropsychological tests measuring different aspects of working memory, than the healthy control group, which indicates a dysfunction of the prefrontal cortex in these patients. This dysfunction may be important in the etiology of many psychosomatic diseases, including psoriasis and affective disorders and may be associated with abnormal activity of neurotransmitter systems in the brain. Disorders associated with cognitive impairment, such as schizophrenia and affective disorders, have been found to be associated with dysfunction in various neurotransmitter systems, crucial for the efficient activity of the prefrontal cortex of the brain, including dopaminergic, serotonergic, GABAergic and noradrenergic systems. These systems play an important role in cognitive and emotional processes as well as the resistance to stress [21, 22]. Perhaps cognitive dysfunctions in psoriasis have similar determinants. Results of the present study also indicate a significant prevalence of depression in psoriasis patients, which in over half of the studied sample reached the clinical level. In these patients, BDI scores were between 12 and 32 points, with means intensity of depressive symptoms of 18.2 points. The BDI results correlated positively with psoriasis severity and negatively with duration of illness, which may be the effect of adjustment to the disease and coping with its psychosocial consequences. This confirms that psoriasis and depression may co-occur. Moreover, the severity of depressive symptoms in some patients indicate the need for their better recognition and plausibility of anti-depressive treatment. These results are concordant with those obtained by the German authors who observed a larger prevalence of depression, as well as the relationship between its severity and quality of life in patients with psoriasis [23]. Compared to healthy controls, psoriasis patients show significantly worse results (longer time of performance) in both parts of the TMT test used for the evaluation of visuo-spatial working memory. While the level of TMT A performance in psoriasis patients indicates psychomotor slowness, worse results in the TMT B are connected with prefrontal cortex disturbances. These result in poorer set shifting and cognitive control, poorer visuospatial memory, and impairment of executive control. Similarly, in terms of verbal working memory, they obtained worse results in the Stroop Test (especially part B), compared to healthy subjects. Contrary to our hypotheses, the results obtained by psoriasis patients in all neuropsychological tests were not related to the severity of depressive symptoms, such relationship being observed in patients with the diagnosis of depression in the course of affective disorders [12]. No relationship was also found between the efficiency of cognitive functions and severity of psoriasis indicated by the PASI score. Likewise, no such relationship was found with the duration of the last exacerbation of the disease. Interestingly, longer duration of psoriasis correlated with significantly worse results in neuropsychological tests. This may indicate progressive changes within the central nervous system (CNS), especially in the prefrontal cortex. This phenomenon is difficult to interpret, however the adverse effects of inflammatory factors (cytokines, cortisol) on the nervous system during the course of the disease have one possible cause. It was proven, in the affective disorders, that cortisol can have neurotoxic effects, especially for the hippocampal neurons, involved in the declarative memory and emotional processes. This hypothesis is supported by data from multiple studies that established that the nervous, immune and endocrine systems behave as a functional unity. These systems communicate and interact with each other using neurotransmitters, hormones, or cytokines, problems in the one of them affecting the functioning of the others [24, 25]. Damage to the nervous system, especially to the hippocampus and the hypothalamus, affects the function of the thymus and production of T cells. Moreover, cytokine receptors are present together with neurotransmitter receptors on the same cells. Receptors for interleukin (IL)-1, IL-2, and IL-6 are present within the structure of the hypothalamus and the hippocampus, IL-1, and IL-6 are continuously produced at low concentrations in neurons and glia. In the course of somatic disorders, in which increased synthesis of pro-inflammatory cytokines is observed, symptoms of depression or a higher risk of developing symptoms of depression, were documented. The depression cytokines modulate the function of the brain, affecting sleep patterns, appetite, and cognitive functions [26, 27]. The hypothalamic-pituitary-adrenal (HPA) axis is stimulated on all levels by proinflammatory cytokines. At the same time glucocorticoids secreted due to the stimulation of the limbic-hypothalamic-pituitary-adrenal (LHPA) axis interact with immunosuppressants [28-30]. Both in psoriasis and depression, pathological proinflammatory immune readiness has been observed [31, 32]. Finally, on the psychological level, early onset of the skin disease can be an element of dysfunctional depressive cognitive schema, and thus may facilitate the occurrence of depression. One of the factors of protecting properties to cognitive functions, is cognitive activity. The current study demonstrated a relationship between higher levels of education and better efficiency of the tested functions, especially in healthy subjects. In the patient group, a significant correlation between education and neuropsychological test results was observed, however, it pertained only to the two tests, i.e. Stroop Test Part A and Part A of the TMT test. While psychomotor speed and overall verbal functions efficiency in psoriasis patients are associated with a higher level of education, this relationship was not observed in the case of complex executive frontal functions measured by Stroop B and TMT B tests. The performance in these tests requires efficient working memory and executive functions associated with the prefrontal cortex activity. While higher levels of education correlated with higher efficacy of these functions in healthy subjects, this effect may be hampered by the psoriasis-related dysfunctions of prefrontal cortex in our group of patients. Moreover, according to the current data, etiology of depression and cognitive dysfunctions is associated with abnormalities in similar brain structures, such as prefrontal cortex and hippocampus. It may also explain the high incidence of neuropsychiatric symptoms in psoriasis, namely the anxiety, irritability and depressive symptoms associated with CNS dysfunction [33]. This suggests potential usefulness of mental training, e.g. neuropsychological therapy, in patients with psoriasis whose cognitive functions are impaired. Stress and depression accompanying psoriasis are well-recognized risk factors for cardiovascular events and thus may increase the risk of developing dementia. This is especially important for older patients, in which the effect of aging on cognition can be accompanied by the aforementioned risk factors. This indicates the plausibility of early screening for the symptoms of mild cognitive impairment (MCI), which are considered an intermediate stage between normal aging and dementia, especially in older patients (60–65 years old), experiencing subjective decline in intellectual fitness [32]. This can be done using standard screening tools, such as the Mini-Mental State Examination (MMSE). Inconclusive results can be accompanied by full neuropsychological examination.

Conclusions

Patients with psoriasis show a significant impairment of prefrontal neuropsychological functions, which are independent from the level of depression and severity of the illness.
  29 in total

1.  Integrity of the mesocortical dopaminergic system is necessary for complete expression of in vivo hippocampal-prefrontal cortex long-term potentiation.

Authors:  H Gurden; J P Tassin; T M Jay
Journal:  Neuroscience       Date:  1999       Impact factor: 3.590

2.  A multivariate analysis of clinical severity, psychological distress and psychopathological traits in psoriatic patients.

Authors:  Lena Kotrulja; Meri Tadinac; Nata A Joki-Begi; Rudolf Gregurek
Journal:  Acta Derm Venereol       Date:  2010-05       Impact factor: 4.437

Review 3.  Psoriasis and physical activity: a review.

Authors:  P B Wilson; K A Bohjanen; S J Ingraham; A S Leon
Journal:  J Eur Acad Dermatol Venereol       Date:  2012-03-05       Impact factor: 6.166

4.  The relationship between stress and the onset and exacerbation of psoriasis and other skin conditions.

Authors:  M S Al'Abadie; G G Kent; D J Gawkrodger
Journal:  Br J Dermatol       Date:  1994-02       Impact factor: 9.302

5.  Different expression of cytokine and membrane molecules by circulating lymphocytes on acute mental stress in patients with atopic dermatitis in comparison with healthy controls.

Authors:  G Schmid-Ott; B Jaeger; S Meyer; E Stephan; A Kapp; T Werfel
Journal:  J Allergy Clin Immunol       Date:  2001-09       Impact factor: 10.793

6.  Mild cognitive impairment in patients with moderate to severe chronic plaque psoriasis.

Authors:  Paolo Gisondi; Francesca Sala; Franco Alessandrini; Virginia Avesani; Giada Zoccatelli; Alberto Beltramello; Giuseppe Moretto; Giuseppe Gambina; Giampiero Girolomoni
Journal:  Dermatology       Date:  2014-01-11       Impact factor: 5.366

7.  Cognitive function across manic or hypomanic, depressed, and euthymic states in bipolar disorder.

Authors:  Anabel Martínez-Arán; Eduard Vieta; María Reinares; Francesc Colom; Carla Torrent; Jose Sánchez-Moreno; Antonio Benabarre; José Manuel Goikolea; Mercè Comes; Manel Salamero
Journal:  Am J Psychiatry       Date:  2004-02       Impact factor: 18.112

Review 8.  Measures of anxiety: State-Trait Anxiety Inventory (STAI), Beck Anxiety Inventory (BAI), and Hospital Anxiety and Depression Scale-Anxiety (HADS-A).

Authors:  Laura J Julian
Journal:  Arthritis Care Res (Hoboken)       Date:  2011-11       Impact factor: 4.794

9.  Neuronal plasticity of the "brain-skin connection": stress-triggered up-regulation of neuropeptides in dorsal root ganglia and skin via nerve growth factor-dependent pathways.

Authors:  Ricarda A Joachim; Arne Kuhlmei; Q Thai Dinh; Bori Handjiski; Tanja Fischer; Eva M J Peters; Burghard F Klapp; Ralf Paus; Petra C Arck
Journal:  J Mol Med (Berl)       Date:  2007-07-17       Impact factor: 4.599

10.  Itch, disease coping strategies and quality of life in psoriasis patients.

Authors:  Alicja Ograczyk; Joanna Miniszewska; Anna Kępska; Anna Zalewska-Janowska
Journal:  Postepy Dermatol Alergol       Date:  2014-10-22       Impact factor: 1.837

View more
  7 in total

1.  Cognitive impairment in patients with psoriasis: A clinical study in teaching hospital.

Authors:  Kumari Padma; Sagar Subhash Nanaware; Aruna Yadiyal; P John Mathai
Journal:  J Family Med Prim Care       Date:  2020-08-25

Review 2.  Cognitive impairment in elderly patients with rheumatic disease and the effect of disease-modifying anti-rheumatic drugs.

Authors:  Akhil Sood; Mukaila A Raji
Journal:  Clin Rheumatol       Date:  2020-08-30       Impact factor: 2.980

3.  Cognitive load and emotional processing in psoriasis: a thermal imaging study.

Authors:  Maria Serena Panasiti; Giorgia Ponsi; Bianca Monachesi; Luigi Lorenzini; Vincenzo Panasiti; Salvatore Maria Aglioti
Journal:  Exp Brain Res       Date:  2018-10-29       Impact factor: 1.972

4.  Psoriasis and Dementia: A Cross-sectional Study of 121,801 Patients.

Authors:  Khalaf Kridin; Dennis Linder; Guy Shalom; Stefano Piaserico; Meir Babaev; Tamar Freud; Doron Comaneshter; Arnon D Cohen
Journal:  Acta Derm Venereol       Date:  2020-08-19       Impact factor: 3.875

5.  Cognition/Psychological Burden and Resilience in Cutaneous T-Cell Lymphoma and Psoriasis Patients: Real-Life Data and Implications for the Treatment.

Authors:  Giovanni Damiani; Joselin D Tacastacas; Timothy Wuerz; Lindsay Miller; Philip Fastenau; Christopher Bailey; Mansi Sethi Chawa; Amanda Argenas; Marco Fiore; Kevin D Cooper; Alan J Lerner
Journal:  Biomed Res Int       Date:  2022-07-21       Impact factor: 3.246

6.  The Potential Role of Serum Tau Protein (MAPT), Neuronal Cell Adhesion Molecule (NrCAM) and Neprilysin (NEP) in Neurodegenerative Disorders Development in Psoriasis-Preliminary Results.

Authors:  Anna Baran; Julia Nowowiejska; Justyna Magdalena Hermanowicz; Beata Sieklucka; Julita Anna Krahel; Paulina Kiluk; Dariusz Pawlak; Iwona Flisiak
Journal:  J Clin Med       Date:  2022-08-27       Impact factor: 4.964

7.  A preliminary study about neurofilament light chain and tau protein levels in psoriasis: Correlation with disease severity.

Authors:  Gokhan Okan; Adile Merve Baki; Eda Yorulmaz; Semra Doğru-Abbasoğlu; Pervin Vural
Journal:  J Clin Lab Anal       Date:  2020-09-08       Impact factor: 2.352

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.